Ecallantide Antibodies: Clinical Safety and Efficacy Evaluation in Treatment of Acute HAE Attacks

2011 ◽  
Vol 127 (2) ◽  
pp. AB266-AB266
Author(s):  
H.H. Li ◽  
P.T. Horn ◽  
W.T. Pullman
2021 ◽  
Author(s):  
Clara Serrano Zueras ◽  
Verónica Guilló Moreno ◽  
Martín Santos González ◽  
Francisco Javier Gómez Nieto ◽  
Göran Hedenstierna ◽  
...  

2021 ◽  
pp. 106002802110098
Author(s):  
Linguang Gan ◽  
Xiaohong Zhao ◽  
Xiangjian Chen

Background: This study systematically evaluated the safety and efficacy of dexmedetomidine for procedural sedation and postoperative behaviors in a pediatric population as well as whether the results met the information required to draw conclusions. Objective: To evaluate the safety and efficacy evaluation of dexmedetomidine for procedural sedation and postoperative behaviors in a pediatric population. Methods: PubMed, Cochrane library, Web of Science and Ovid MEDLINE were searched to obtain randomized controlled trials (RCTs) comparing dexmedetomidine with control medicine and comparing different doses of dexmedetomidine. Results: There were a total of 16 RCTs for a total of 3240 patients. Dexmedetomidine slowed down the heart rate (HR; mean difference: −13.27; 95% CI: −16.41 to 10.14; P < 0.001) and reduced postoperative delirium (risk ratio [RR]: 0.31; 95% CI: 0.20-0.50; P < 0.001), the number of pain patients (RR: 0.48; 95% CI: 0.30-0.75; P = 0.002), and desaturation (RR: 0.34; 95% CI: 0.13-0.89; P = 0.03) compared with the control group. The limitation was that it was difficult to determine the range of low- and high-dose dexmedetomidine. Conclusion and Relevance: Dexmedetomidine slowed down intraoperative HR within the normal range, which might reduce myocardial oxygen consumption. It reduced postoperative pain and postoperative complications: delirium and desaturation. Dexmedetomidine showed no dose-dependent increase in the procedural sedation time of pediatric patients. Clinically, dexmedetomidine can improve pediatric procedural sedation and postoperative behavior, and it can be considered as a related medicine for safety in pediatric surgery.


PEDIATRICS ◽  
1983 ◽  
Vol 71 (1) ◽  
pp. 137-137
Author(s):  
THOMAS W. SMITH

To the Editor.— Accompanying the paper of Zucker et al in the September issue of Pediatrics1 is a listing of sources from which digoxin-specific Fab fragments are stated to be available. Unfortunately, this is no longer the case. All of the individuals and institutions listed have been part of a multicenter trial of clinical safety and efficacy of purified digoxin-specific Fab fragments in the treatment of advanced, life-threatening digitalis toxicity. At the present time, however, supplies of the material are extremely limited, and several of the centers listed have exhausted their supplies of digoxin-specific Fab fragments.


2018 ◽  
Vol 30 (6) ◽  
pp. 605-611 ◽  
Author(s):  
Ke-Jia Lv ◽  
Tian-Chi Chen ◽  
Guo-Hua Wang ◽  
Ya-Nan Yao ◽  
Hua Yao

Sign in / Sign up

Export Citation Format

Share Document